Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $92.57 Analyst target: $140.53 Upside: 51.81%
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.